GNRHR Signaling in Hematologic Cancer Cell Lines

Publique

MLA citation style (9th ed.)

Schubach, Emily, and Steding, Catherine E. Gnrhr Signaling In Hematologic Cancer Cell Lines. . 2023. marian.palni-palci-staging.notch8.cloud/concern/generic_works/1c08dba5-f768-49e7-9160-cc487aaf1631?locale=fr.

APA citation style (7th ed.)

S. Emily, & S. C. E. (2023). GNRHR Signaling in Hematologic Cancer Cell Lines. https://marian.palni-palci-staging.notch8.cloud/concern/generic_works/1c08dba5-f768-49e7-9160-cc487aaf1631?locale=fr

Chicago citation style (CMOS 17, author-date)

Schubach, Emily, and Steding, Catherine E.. Gnrhr Signaling In Hematologic Cancer Cell Lines. 2023. https://marian.palni-palci-staging.notch8.cloud/concern/generic_works/1c08dba5-f768-49e7-9160-cc487aaf1631?locale=fr.

Note: These citations are programmatically generated and may be incomplete.

GnRHR signaling has been demonstrated to affect cancer cell proliferation. The expression of GnRH binding sites in leukemias and lymphomas provides a potential target for chemotherapeutic drugs. Analyzing the effect of GnRHR targeted therapy in non-reproductive cancers is a novel and underexplored project that may contribute to the understanding of directed hormonal signaling in hematologic cancers. The goal of this project is to elucidate the potential effects of targeting the GnRHR pathway in hematologic cell proliferation. Additionally, chemotherapeutic drugs that are not typically used to treat hematological cancers (such as Paclitaxel) may provide useful information about mechanisms of chemoresistance. Because of the demonstrated sensitivity of HL-60 cells to Paclitaxel, gradually increasing the dosage from an initially small dose can provide valuable information in regard to the development of chemoresistance to this particular drug.

Creator
Language
Mot-clé
Date created
Resource type
Rights statement

Relations

Dans Collection:

Contenu